Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RKI983A · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| RKI983A | DRUG | RKI983 0.05 % twice daily |
| Latanoprost | DRUG | Latanoprost 0.005 % once a day |
Inclusion Criteria: * Females must be post-menopausal or surgically sterile, or must use concomitantly two acceptable forms of effective contraception * Clinical diagnosis of POAG or OH * For study eyes not previously treated with anti-glaucoma medications * IOP must be ≥ 22 mm Hg at least at tw...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Timolol eye 0.5% |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Undisclosed |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| Alcon AG | ALC | 5 | N/A | Undisclosed |
| Sight Sciences, Inc. | SGHT | 3 | N/A | Undisclosed |
RKI983 is an investigational small molecule being developed for the treatment of glaucoma and ocular hypertension. It is intended for use in patients with primary open-angle glaucoma (POAG) or ocular hypertension, and is administered as an eye drop.
RKI983 is being developed by Novartis AG, a multinational pharmaceutical company listed on the New York Stock Exchange under the ticker symbol NVS. The drug is currently in Phase 1 clinical development.
RKI983 is in Phase 1 clinical development. It has completed one Phase 1 trial, and it is not yet approved by the FDA. The drug remains investigational and is still in the early stages of clinical testing.
RKI983 has one completed clinical trial, NCT00846989, which evaluated the efficacy, tolerability, and safety of RKI983 at 0.05% and 0.10% concentrations compared to Xalatan in patients with POAG or ocular hypertension. The trial enrolled 276 participants in the United States.
No, RKI983 is not the same as Xalatan. In the clinical trial NCT00846989, RKI983 was compared against Xalatan as an active control. Xalatan is a prostaglandin analog used to lower intraocular pressure, while RKI983 is a separate investigational compound.